Completed PHASE3 INTERVENTIONAL NCT00214877

Methylene Blue for Cognitive Dysfunction in Bipolar Disorder

Double-Blind Trial of Methylene Blue for Cognitive Dysfunction in Bipolar Disorder

Sponsor: Nova Scotia Health Authority

Updated 5 times since 2017 Last updated: Mar 28, 2008 Started: Nov 30, 2003 Completion: Oct 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00214877, this PHASE3 trial focuses on Bipolar Disorder and remains completed. Sponsored by Nova Scotia Health Authority, it has been updated 5 times since 2003, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Nov 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nova Scotia Health Authority
Stanley Medical Research Institute

Data source: Nova Scotia Health Authority

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Halifax, Canada
• Hamilton, Canada